Quantum BioPharma Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
QNTM Nasdaq 2834 www.quantumbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quantum BioPharma Ltd.

Quantum BioPharma Provides Corporate Update - Mar 10th, 2026 5:45 pm
Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) - Dec 23rd, 2025 6:00 am
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares - Dec 22nd, 2025 7:00 am
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update - Dec 10th, 2025 6:00 pm
Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC - Dec 1st, 2025 5:00 am
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC - Nov 28th, 2025 7:30 am
Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC - Nov 27th, 2025 2:00 pm
Quantum Biopharma’s USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5 - Nov 26th, 2025 7:30 am
Quantum BioPharma Ltd. Provides Corporate Update - Oct 31st, 2025 5:51 pm
Quantum BioPharma Ltd. Announces Corporate Updates - Oct 29th, 2025 7:00 pm
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication - Oct 23rd, 2025 6:15 am
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend - Oct 20th, 2025 6:30 am
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group - Oct 14th, 2025 6:15 am
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock - Oct 8th, 2025 6:00 am
Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View - Oct 7th, 2025 9:00 am
Quantum Biopharma Set Oct. 27 as Record Date For CVRs Distribution Tied to Future Settlement Proceeds - Oct 3rd, 2025 6:45 am
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case - Oct 3rd, 2025 5:00 am
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial - Oct 2nd, 2025 5:57 am
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials - Oct 1st, 2025 5:50 am
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders - Sep 29th, 2025 5:40 am